FDA Meeting – Risk Benefit Assessment

Testimony Delivered at the FDA Public Meeting on Benefit-Risk Assessments in Drug Regulatory Decision-Making September 18, 2017 [FDA Docket No. FDA-2017-N-4076]   My name is Caila Brander and I am the Policy Coordinator at The National Women’s Health Network, a nonprofit advocacy organization that works to improve the health of all women. We are supported … Continued